MTOR and hematologic disorder: There is an increased risk of HEV persistence in patient populations under immunosuppression after solid organ transplantation receiving calcineurin inhibitors, corticosteroids, mycophenolic acid, cyclosporine A, or mammalian target of rapamycin (mTOR) inhibitors, often administered as combined drug therapy [6,7,8], and in patients with hematological malignancies [9].